Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D Rx Use Shows “Little Change” As Enrollees Enter Coverage Gap, CMS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS gives first glimpse at the kind of Part D drug claims data that will become available to researchers in December.

You may also be interested in...



Nearly A Quarter Of Diabetes Patients Altered Therapy In Part D Gap – Study

Twenty-three percent of a large sample of Medicare Part D enrollees taking oral drugs for diabetes changed their medication use when they reached the gap in coverage, according to a study released by the Kaiser Family Foundation Aug. 21

Part D Drug Data Expected To Be Available For Research Dec. 1

CMS is targeting Dec. 1 as the date for opening Medicare Part D drug claims data to both government and independent researchers

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Topics

UsernamePublicRestriction

Register

PS067079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel